Market Herald logo

Subscribe

Be the first with the news that moves the market
  • The BC Bud Corporation (BCBC) has closed a non-brokered private placement raising gross proceeds of $340,000
  • The company issued 6,800,000 units at $0.05 per unit
  • The company plans to use the proceeds of the placement for business development and general working capital purposes
  • The BC Bud Co is a British Columbia-based cannabis company
  • The BC Bud Corporation opened trading at $0.075

The BC Bud Corporation (BCBC) has closed a non-brokered private placement for gross proceeds of $340,000.

The company issued 6,800,000 units at a price of $0.05 per unit. Each unit consisted of one common share and one share purchase warrant. Each warrant entitles the holder to acquire an additional common share at a price of $0.15 per share until February 2, 2025.

All securities issuable in the placement are subject to a statutory four-month hold period expiring on June 3, 2023.

No finders fees were payable in connection with the placement.

The company plans to use the proceeds for business development and general working capital purposes.

The BC Bud Corporation is a British Columbia-based cannabis company. 

The BC Bud Corporation opened trading at $0.075.


More From The Market Herald

" ParcelPal (CSE:PKG) relaunches a new and improved mobile application

ParcelPal Logistics (PKG) will relaunch its mobile delivery application on a rolling basis over the coming months.

" Puma Exploration (TSXV:PUMA) confirms mineralization

Puma Exploration (PUMA) is confirming mineralization at its Williams Brook Gold Project in Northern New Brunswick.
Flying Nickel Mining

" Flying Nickel (TSXV:FLYN) confirms platinum, palladium, gold mineralization

Flying Nickel Mining (FLYN) is confirming, it uncovered gold mineralization from the most-recent drill program on its Minago Nickel PGM Project.

" NervGen Pharma (TSXV:NGEN) releases year-end operational highlights

NervGen Pharma (NGEN) reports 2022 year-end operational highlights and looks to start a phase 1b/2a clinical trial in Q3 2023.